PPARG and cancer: Notably, the PPARγ agonist rosiglitazone has been shown to delay anorexia and attenuate adipose tissue loss in murine models of cancer cachexia, suggesting that central PPARγ signaling plays a protective role in mitigating anorexia and systemic wasting (43).